Erythema Multiforme in Dogs: Severe Skin Reactions

By Emiel Maddens  ·  Reviewed in consultation with licensed veterinary professionals  ·  Updated June 2026  ·  10 min read

Photo by Anya Prygunova on Unsplash

Erythema multiforme (EM) is an uncommon but clinically significant immune-mediated skin condition that can affect dogs of any age, breed, or sex. The condition develops when the immune system mounts an aberrant response to a triggering agent, most commonly a medication or infectious organism, that results in targeted destruction of skin cells. This immunological attack produces the distinctive clinical features of EM: well-defined, often ring-shaped or target-like skin lesions that can range from mild, self-limiting patches to severe, widespread skin detachment that constitutes a medical emergency. Understanding the clinical spectrum, triggers, and treatment of EM is essential for prompt recognition and appropriate intervention.

The pathogenesis of EM involves cell-mediated cytotoxicity directed against keratinocytes (skin cells) that have been altered by the triggering agent. Drug molecules or infectious antigens bind to or are processed by keratinocytes, rendering them targets for cytotoxic T-lymphocytes that recognize the altered cells as foreign. The resulting immune attack causes keratinocyte apoptosis (programmed cell death), which produces the clinical lesions visible on the skin surface. The intensity of this immune response determines where the condition falls on the severity spectrum, from the relatively mild EM minor through the intermediate Stevens-Johnson syndrome (SJS) to the most severe form, toxic epidermal necrolysis (TEN), which involves detachment of large areas of skin.

Veterinary recognition of EM has improved significantly in recent decades, but the condition remains challenging to diagnose promptly because its early lesions can resemble other dermatological conditions, including urticaria (hives), autoimmune blistering diseases, and even infectious skin conditions. The key to effective management is rapid identification of the trigger, immediate withdrawal of any suspected causative medication, and aggressive supportive care proportional to the severity of the skin involvement. For mild cases, recovery is typically complete within a few weeks. For severe cases on the SJS/TEN spectrum, the condition can be life-threatening and requires intensive care management similar to that provided for severe burn patients.

Understanding Erythema Multiforme

The Immune-Mediated Mechanism

Erythema multiforme is classified as a type IV hypersensitivity reaction, meaning it is mediated by T-lymphocytes rather than antibodies. When a triggering agent, whether a drug metabolite, infectious antigen, or other substance, is presented on the surface of keratinocytes, CD8+ cytotoxic T-cells recognize these altered cells and initiate targeted destruction. The T-cells release perforin and granzymes, which are cytotoxic molecules that punch holes in the keratinocyte membranes and trigger intracellular apoptotic pathways. Additional cytokines, including tumor necrosis factor-alpha and Fas ligand, amplify the destructive response. The result is widespread keratinocyte apoptosis that, depending on its extent, produces the clinical spectrum from mild erythematous patches to full-thickness epidermal detachment.

Classification on the Severity Spectrum

The EM spectrum encompasses three clinical entities of increasing severity. EM minor involves less than 10% of the body surface area and produces characteristic target-like lesions without significant mucosal involvement. Stevens-Johnson syndrome (SJS) involves 10% to 30% of the body surface with bullae (blisters), skin detachment, and frequent involvement of mucous membranes at the lips, eyes, nose, and genitalia. Toxic epidermal necrolysis (TEN) is the most severe form, involving greater than 30% of the body surface with extensive, sheet-like epidermal detachment, severe mucosal involvement, and systemic complications including fluid loss, protein depletion, hypothermia, and sepsis. The mortality rate for TEN in dogs is significant, reported at 30% to 50% in some case series.

How Common Is EM in Dogs

Erythema multiforme is an uncommon condition in dogs, though exact incidence figures are difficult to establish because mild cases may resolve without definitive diagnosis. The condition can affect dogs of any age, breed, or sex, though some studies have suggested a slight predisposition in middle-aged dogs. There are no well-established breed predispositions, though individual dogs may have genetic factors that influence their susceptibility to specific drug reactions. The relative rarity of the condition means that many general practice veterinarians may encounter only a handful of cases during their careers, potentially contributing to diagnostic delays.

Common Triggers of Erythema Multiforme

Drug-Induced Reactions

Medications are the most commonly identified triggers of EM in dogs, with certain drug classes carrying higher risk than others. Trimethoprim-sulfonamide antibiotics are among the most frequently implicated agents, with reactions typically developing 1 to 3 weeks after the initiation of therapy. Cephalosporin antibiotics, penicillins, and fluoroquinolones have also been reported as triggers. Non-steroidal anti-inflammatory drugs (NSAIDs), including carprofen, meloxicam, and deracoxib, can trigger EM in susceptible individuals. Anticonvulsant medications, particularly phenobarbital and potassium bromide, represent another important drug category associated with EM development. Importantly, a drug that a dog has tolerated previously without problems can still trigger EM upon subsequent exposure, as the immune system may require multiple exposures to develop the sensitization that leads to the reaction.

Infection-Related Triggers

Infectious agents can trigger EM by providing antigens that, when processed and presented by keratinocytes, become targets for cytotoxic immune responses. Bacterial infections, particularly staphylococcal skin infections, have been associated with EM development in dogs. Viral infections, including herpesvirus and parvovirus, have been reported as triggers in some cases. Fungal infections, including dermatophytosis, have occasionally been linked to EM. In many cases, the infection itself may have prompted the prescription of antibiotics, creating a diagnostic dilemma about whether the trigger is the infection, the medication used to treat it, or the combination of both factors.

Idiopathic Cases

In a significant proportion of canine EM cases, estimated at 20% to 50% depending on the study, no specific trigger can be identified despite thorough investigation. These idiopathic cases present management challenges because the inability to identify and eliminate the trigger makes recurrence prevention difficult. In some idiopathic cases, the trigger may be a subclinical infection, a dietary component, an environmental exposure, or a vaccine reaction that is not recognized at the time of clinical presentation. Careful documentation of all medications, dietary changes, environmental exposures, and health events in the weeks preceding the onset of EM can sometimes reveal a previously overlooked potential trigger.

Emergency veterinary care is critical for severe drug-induced skin reactions.

Photo by Tima Miroshnichenko on Pexels

Clinical Signs and Recognition

Target Lesions and Classic Presentation

The hallmark lesion of erythema multiforme is the target or iris lesion, which consists of concentric rings of different colors surrounding a central area. In its classic form, the target lesion shows a central zone of darkened or blistered skin, surrounded by a pale or edematous ring, which is in turn enclosed by a red or erythematous outer ring. While these classic target lesions are highly suggestive of EM when present, they are not always fully developed in canine cases, and atypical target lesions with fewer distinct zones are more common. The lesions may be flat (macular), raised (papular), or blistered (vesicular or bullous), and they tend to be distributed on the ventral trunk, axillae, groin, mucocutaneous junctions, and ear pinnae.

Mucosal and Mucocutaneous Involvement

Involvement of the mucous membranes and mucocutaneous junctions is an important clinical feature that distinguishes more severe forms of EM from the milder EM minor. Oral mucosal lesions produce ulceration of the gums, tongue, palate, and inner lips, causing pain, drooling, and reluctance to eat. Ocular involvement can produce conjunctivitis, corneal ulceration, and eyelid adhesions that may cause lasting visual impairment. Nasal, genital, and anal mucosal involvement adds to the patient's discomfort and creates additional surfaces susceptible to secondary infection. The extent and severity of mucosal involvement is one of the key factors determining the overall severity classification and prognosis.

Systemic Signs in Severe Cases

Dogs with SJS or TEN often exhibit systemic signs that reflect the severity of the skin and mucosal involvement. Fever, lethargy, decreased appetite, and dehydration develop as the body's protective skin barrier is compromised. Pain is a significant component, as extensive epidermal detachment exposes the raw, nerve-rich dermis. In TEN, the skin may detach in sheets with gentle pressure (positive Nikolsky sign), and the exposed dermis weeps serum, leading to significant fluid and protein loss. Secondary bacterial infection of the denuded skin surfaces can progress to sepsis, which is the most common cause of mortality in TEN patients.

Diagnosis and Differential Diagnoses

Skin Biopsy as Gold Standard

Definitive diagnosis of EM requires skin biopsy with histopathological examination. The characteristic findings include individual keratinocyte apoptosis (cell-by-cell death) at multiple levels of the epidermis, lymphocytic satellitosis (lymphocytes surrounding individual apoptotic keratinocytes), and a lymphocyte-predominant interface dermatitis at the dermo-epidermal junction. In severe cases, full-thickness epidermal necrosis with subepidermal blistering is observed. Multiple biopsies from lesions of different ages and types improve diagnostic accuracy. Biopsies should be taken from active, evolving lesions rather than older, resolving ones.

Conditions That Mimic EM

Several dermatological conditions can produce lesions that resemble EM, and these must be differentiated through biopsy and clinical evaluation. Pemphigus vulgaris produces mucosal and cutaneous blistering that can mimic SJS/TEN. Bullous pemphigoid produces subepidermal blisters similar to those seen in severe EM. Systemic lupus erythematosus can produce target-like lesions and mucocutaneous erosions. Drug eruptions without the specific EM pattern can produce widespread skin lesions that superficially resemble EM. Thermal or chemical burns can mimic TEN when skin detachment is extensive. Accurate histopathological classification is essential for appropriate treatment selection.

A thorough medication and exposure history is an integral part of the diagnostic process. The veterinarian will compile a complete list of all medications, supplements, vaccines, and topical products the dog has received in the 1 to 4 weeks preceding the onset of skin lesions. Any recent infections, dietary changes, or environmental exposures are also documented. This information is critical both for identifying the likely trigger and for preventing future episodes by avoiding re-exposure.

Emergency Treatment for Severe Cases

Immediate Trigger Removal

The single most important therapeutic intervention in EM is the identification and immediate discontinuation of the triggering agent. If a medication is suspected, it should be stopped immediately and replaced with an alternative from a different drug class if ongoing treatment for the underlying condition is needed. In drug-induced EM, clinical improvement typically begins within 48 to 72 hours of stopping the offending medication, though complete resolution may take weeks. If an infection is the suspected trigger, appropriate antimicrobial therapy directed at the infectious agent is initiated. In idiopathic cases, any recently introduced medication, supplement, or dietary change should be discontinued as a precautionary measure.

Intensive Care for SJS and TEN

Dogs with SJS or TEN require hospitalization and intensive care management similar to that provided for severe burn patients. Intravenous fluid therapy corrects dehydration and ongoing fluid losses from the denuded skin surfaces. Nutritional support through assisted feeding or, in severe cases, enteral tube feeding maintains caloric and protein intake during the recovery period. Pain management with opioid analgesics and gabapentin addresses the significant discomfort associated with extensive skin detachment. Temperature regulation is essential, as loss of the insulating skin barrier leads to hypothermia.

Wound Care and Infection Prevention

The exposed dermis in SJS/TEN patients is highly susceptible to bacterial colonization and infection, making meticulous wound care a critical component of management. Non-adherent dressings protect the raw skin surfaces and minimize pain during bandage changes. Topical antimicrobial agents, including silver sulfadiazine or chlorhexidine-based products, help prevent bacterial infection of the denuded areas. Systemic antibiotics are reserved for cases with confirmed secondary infection, as prophylactic antibiotic use increases the risk of selecting for resistant organisms. Frequent, gentle wound assessment guides dressing changes and allows early detection of infection.

Recovery Timeline and Prognosis

EM Minor Recovery

Dogs with EM minor, the mildest form of the condition, generally have an excellent prognosis. Once the trigger is identified and removed, new lesions typically stop developing within 48 to 72 hours, and existing lesions begin to resolve. Complete skin healing usually occurs within 2 to 4 weeks, with lesions resolving through crusting, flaking, and gradual re-epithelialization. Some residual hyperpigmentation or mild scarring may persist at the sites of resolved lesions but is generally cosmetically minor. Dogs that recover from EM minor usually return to completely normal health and function.

SJS and TEN Recovery

Recovery from SJS and TEN is considerably more prolonged and uncertain. Dogs that survive the acute phase, typically the first 7 to 14 days, face a recovery period of several weeks to months as the skin regenerates. During this period, strict wound care, nutritional support, and monitoring for complications are essential. Ocular complications, including corneal scarring, keratoconjunctivitis sicca, and symblepharon (adhesion of the conjunctiva to the cornea or eyelid), can produce lasting visual impairment and require ongoing ophthalmological management. Skin healing may be incomplete, with areas of permanent scarring, alopecia, and pigmentation changes. Some dogs experience chronic skin sensitivity in previously affected areas.

Preventing Recurrence

Prevention of EM recurrence centers on permanent avoidance of the identified trigger. If a specific medication triggered the episode, the drug and ideally all medications in the same class should be permanently avoided. This information should be prominently documented in the dog's medical record, and the owner should be informed to communicate the drug sensitivity to any veterinarian who treats the dog in the future. Dogs with idiopathic EM or infection-triggered EM have less predictable recurrence patterns. Any new medication should be introduced cautiously, with owner awareness of the signs of EM so that prompt veterinary attention can be sought if a reaction occurs.

When to Seek Emergency Veterinary Care

Any dog that develops widespread blistering, skin detachment, or erosion of the lips, gums, or eyes should be considered a veterinary emergency. Rapid progression of skin lesions, particularly when accompanied by fever, lethargy, or pain, indicates potential SJS or TEN that requires immediate hospitalization and intensive care. Even milder presentations of EM with characteristic target lesions warrant prompt veterinary evaluation to confirm the diagnosis, identify the trigger, and initiate appropriate management before the condition potentially progresses.

Owners should be particularly vigilant for skin reactions in the 1 to 3 weeks following the introduction of any new medication. Any new skin lesions, facial swelling, oral ulceration, or eye redness that develops during this period should prompt immediate veterinary contact. Early recognition of EM allows for prompt trigger removal and intervention that can limit the severity of the reaction and dramatically improve the outcome. Do not wait to see if the lesions will resolve on their own, as delay in treatment can allow a mild EM reaction to progress to a more severe and potentially life-threatening form.

Erythema Multiforme in Dogs FAQ

Q: What causes erythema multiforme in dogs?

The most common identified triggers are medications, particularly trimethoprim-sulfonamide antibiotics, cephalosporins, NSAIDs, and anticonvulsants. Infections, including bacterial skin infections and viral diseases, can also trigger EM. In 20% to 50% of cases, no specific trigger is identified (idiopathic EM). The underlying mechanism is an immune-mediated attack on skin cells that have been altered by the triggering agent.

Q: Is erythema multiforme contagious?

No, erythema multiforme is not contagious. It is an immune-mediated reaction specific to the individual dog's response to a particular trigger. The condition cannot be transmitted to other animals or humans through contact with the affected dog. However, if the trigger is an infectious agent such as a bacterial or fungal infection, the underlying infection itself may potentially be contagious.

Q: How is erythema multiforme treated?

Treatment begins with identifying and immediately removing the trigger, such as stopping a suspected medication. Mild cases (EM minor) may require only supportive care and monitoring. Moderate to severe cases may need immunosuppressive therapy with corticosteroids or other agents. Severe cases (SJS/TEN) require hospitalization for intensive care, including IV fluids, wound care, pain management, and nutritional support. Topical antimicrobial therapy helps prevent secondary infection of affected skin.

Q: Can erythema multiforme be fatal?

Mild EM minor is not life-threatening and typically resolves completely with trigger removal. However, severe forms on the SJS/TEN spectrum can be fatal, with mortality rates for TEN reported at 30% to 50% in some studies. Death in severe cases is usually caused by sepsis from secondary bacterial infection of the denuded skin, severe fluid and protein loss, or multi-organ dysfunction. Prompt, aggressive veterinary care significantly improves survival odds.

Q: Will my dog react to the same medication again?

Yes. If a specific medication triggered the EM reaction, re-exposure to the same drug will very likely trigger another reaction, potentially more severe than the first episode. The offending medication and ideally all medications in the same drug class should be permanently avoided. This drug sensitivity should be clearly documented in the dog's medical records and communicated to all veterinary professionals who may treat the dog.

Sources

Scott, D.W., Miller, W.H. (1999). Erythema multiforme in dogs and cats: literature review and case material from the Cornell University College of Veterinary Medicine. Veterinary Dermatology, 10(4), 297-309.

Hinn, A.C., Olivry, T., Luther, P.B., Cannon, A.G., Yager, J.A. (1998). Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis in the dog: clinical classification, drug exposure, and histopathological correlations. Veterinary Allergy and Clinical Immunology, 6, 13-20.

Nuttall, T.J., Malham, T. (2004). Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog. JSAP, 45(7), 357-361.

Mellor, P.J., Roulois, A.J., Day, M.J., Sherrill, S., Sherburne, B., Fitzgerald, J.R. (2006). Neutrophilic dermatitis and immune-mediated haematological disorders in a dog: suspected adverse reaction to carprofen. JSAP, 47(11), 689-693.

Gross, T.L., Ihrke, P.J., Walder, E.J., Affolter, V.K. (2005). Skin Diseases of the Dog and Cat, 2nd ed. Blackwell Publishing. Chapter on interface and vesicular dermatitis.

Nemec, A., Zavodovskaya, R., Affolter, V.K., Verstraete, F.J. (2012). Erythema multiforme and epitheliotropic T-cell lymphoma in the oral cavity of dogs. JVIM, 26(5), 1206-1214.

Related Reading

• Drug Eruptions in Dogs, How medications cause adverse skin reactions
• Pemphigus in Dogs, Autoimmune blistering disease with similar presentation
• Hot Spots in Dogs, Acute skin lesions that can be confused with early EM
• Understanding Skin Biopsy Results, How histopathology confirms immune-mediated skin disease
• How Vets Diagnose Skin Problems, Diagnostic methods for complex dermatological conditions

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.